Student pharmacist Johana Suh earned an undergraduate fellowship award for research on 3D bioprinted modeling of the neurodegenerative disease NPC-1, or Niemann-Pick disease type C1. Suh is a second-year Doctor of Pharmacy candidate in the UT College of Pharmacy, and serves as an undergraduate researcher in the Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs led by Mo Maniruzzaman, Ph.D.
Molecular Pharmaceutics and Drug Delivery Professor Maria A. Croyle, Ph.D. received extensive coverage in the March 2021 edition of Texas Monthly regarding her innovative peelable film drug delivery research. Among its many potential applications, Dr. Croyle’s technology could deliver COVID-19 vaccines through a small oral strip, without need for refrigeration or extensive storage and transportation infrastructure.
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle R.Ph., Ph.D. earned 2021’s David Lehr Research Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Dr. Croyle will receive research funding to investigate novel regulatory mechanisms of drug metabolism in the context of active infection with SARS-CoV-2 and after recovery.
Molecular Pharmaceutics and Drug Delivery Professor Robert O. (Bill) Williams III, Ph.D. talks to CBS Austin about the potential for his thin film freezing technology to increase the shelf life of COVID-19 vaccines when they become available.
Nicholas A. Peppas, Sc.D. has been honored with the 2020 Oesper Award from the University of Cincinnati’s Chemistry Department and the Cincinnati Section of the American Chemical Society for his outstanding accomplishments in and contributions to science. The award recognizes his work in biomaterials, drug delivery, bionanotechnology, and nanomaterials.
The newly-formed Jurata Thin Film will work to bring Dr. Maria Croyle's thin film technology to market, allowing biologics and vaccines to be packaged, shipped, and stored at room temperature for extended periods of time.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.